Alkermes
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
POSTED
09-13-21
Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program
Alkermes will begin accepting applications for its annual Alkermes Pathways Research Awards® program on 9/13/2021. This competitive grant program supports researchers working to advance understanding & awareness of disease states in neuroscience.
POSTED
08-24-21
Alkermes Sr. Director of Oncology Discusses Career, Inspirational Women in STEM
Heather Losey Ph.D., Senior Director, Research Oncology Program Lead at Alkermes, sits down with Authority Magazine to discuss her career in a series highlighting inspirational women in STEM.
POSTED
07-23-21
Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program
Grants were awarded to 11 nonprofits working to address the needs of people living with addiction, serious mental illness or cancer, including programs serving historically under-resourced or underrepresented communities.
POSTED
06-24-21
Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign
Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), recently announced former professional baseball player and World Series champion, CC Sabathia, as a spokesperson for the company's My Relationship with Alcohol campaign, which is designed to help raise awareness about the disease of alcoho...
POSTED
05-17-21
The Boston Club Recognizes Alkermes plc and Blue Cross Blue Shield of Massachusetts With First President's Award
Alkermes plc is a recipient of The Boston Club’s first President’s Award, recognizing organizations that are leaders in supporting the advancement of women in the C-suite and boardroom.
POSTED
05-13-21
Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
Alkermes plc (Nasdaq: ALKS) today announced that the company will begin accepting applications for its Alkermes Inspiration Grants® program beginning on May 20, 2021.
POSTED
05-04-21
Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month
Alkermes plc (Nasdaq: ALKS) recently announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in May. The meetings, all held virtually, include:
POSTED
11-04-20
Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic
As the use of telehealth services has expanded during the COVID-19 pandemic, results from a survey conducted by The Harris Poll showed that more than one in four (27%) U.S. adults surveyed were currently using telepsychiatry (“telepsych”) services for mental health care.
POSTED
09-15-20
Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience
Alkermes plc (Nasdaq: ALKS) recently announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at the Psych Congress 2020 Virtual Experience, held Sept. 10-13, 2020.
POSTED
07-29-20
Alkermes Releases Third Annual Corporate Responsibility Report
Alkermes plc (Nasdaq: ALKS) today released its third annual Corporate Responsibility Report. The report highlights the company’s corporate and social responsibility and environmental sustainability efforts, including recognition of the importance of continuing to increase the sophistication of moni...
